Whole-body PET/CT predicts response to HER2-targeted therapy in metastatic breast cancer patients

A new imaging agent, 68Ga-ABY-025, can predict early metabolic response to human epidermal growth factor receptor 2 (HER2)-targeted treatment in HER2-positive metastatic breast cancer patients, according to new research published in the Journal of Nuclear Medicine. By providing whole-body quantification of HER2 expression, 68Ga-ABY-025 PET/CT can play a valuable role in treatment planning and could spare patients from unnecessary drug-related side effects.